Viking Therapeutics (NASDAQ:VKTX) and the Kennedy Krieger Institute announced a sponsored research collaboration focused on evaluating Viking’s thyroid beta agonists for the treatment of X-linked adrenoleukodystrophy (X...
Viking Therapeutics (NASDAQ:VKTX) has submitted an IND application to the FDA to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. Viking expects to initiate the Phase 2...
Titan Pharmaceuticals (NASDAQ:TTNP) has added an implantable triiodothyronine (T3) product for the treatment of hypothyroidism to its product development pipeline. Hypothyroidism affects about 15 million Americans...
Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep Phase 3 placebo-controlled, pivotal clinical trials of Locilex in the treatment of patients with mild infections of diabetic foot ulcers are approximately 62% enrolled...
Avivagen (TSX-V:VIV) and COFCO Nutrition and Health Research Institute (NHRI), an affiliate of the Chinese government’s COFCO Group, have agreed to conduct a trial of OxC-beta Livestock as a feed additive for swine. The...
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study...
Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $17-million for the third quarter this year, an increase of 40% from $12.1-million a year ago. Product sales increased by $5.2-million, or 47%, primarily...
Avivagen (TSX-V:VIV) has agreed with the National Institute of Animal Sciences for Vietnam (NIAS) to conduct a further trial of OxC-beta livestock as a feed additive for swine. Earlier this year, Avivagen and NIAS...
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its CF602 drug candidate showing a defined mechanism of action in erectile dysfunction similar to sildenafil (Viagra) in a rat model of...
President Barack Obama has tackled the opioid epidemic this week by telling health care providers across the country that access to medication-assisted treatment (MAT) must be expanded. He released an order giving...
Viking Therapeutics (NASDAQ:VKTX) has successfully completed a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211 is in development for the treatment of patients...
Twelve-month data from Profound Medical’s (TSXV:PRN) Phase 1 clinical trial of its TULSA-PRO medical device were presented at the European Symposium on Focused Ultrasound Therapy in London. TULSA is a minimally invasive...
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has completed a thorough review of the data from a Phase 2/3 study of ELND005 in Alzheimer’s disease (AD) patients with moderate or severe agitation and aggression. The...
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has entered into definitive agreements with existing institutional investors to receive gross proceeds of about $4.8-million. The company will issue 1,109,196 registered...
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) oncology drug candidate, CF102, has been granted orphan drug designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the...
Cellectar Biosciences (NASDAQ:CLRB) has received initial notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant. The SBIR grant provides up to $2.3-million over 2 1/2 years from the...
Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has entered into a co-marketing agreement with Arthrex, a global medical device company and leader in orthopedic medical device innovation. The agreement allows the two...
Vital Therapies (NASDAQ:VTL) has outlined plans for a possible new Phase 3 clinical trial designed to confirm ELAD’s safety and efficacy in alcohol-induced liver decompensation (AILD), including severe acute alcoholic...
Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has unveiled its SPY-Q Case Manager (SPY-QCM) software at the Symposium on Advanced Wound Care Fall 2015 meeting in Las Vegas. SPY-QCM is an image acquisition and analysis...
BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) Eye-D platform insert will be presented at the 5thAnnual Partnership Opportunities in Drug Delivery conference in Boston on Oct. 5. The Eye-D is BioLight’s...
The United States Patent and Trademark Office has approved Oramed Pharmaceuticals’ (NASDAQ: ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” In a statement, CEO...